Effect of erythropoietin and stem cells on traumatic brain injury
Effect of erythropoietin and stem cells on traumatic brain injury
Yükleniyor...
Abstract
Objective To investigate the healing effects of erythropoietin (EPO) and stem cells (SCs) in traumatic brain injury (TBI). Methods Twenty-nine Wistar albino rats were used and separated into the following groups: control (C), EPO, SC, and SC+EPO. Group C received a TBI only, with no treatment. In the EPO group, 1000 U/kg EPO was given intraperitoneally at 30 minutes after TBI. In SC group, immediately after formation of TBI, 3 × 10,000 CD34 + stem cells were injected into the affected area. In the SC+EPO group, half an hour after TBI and the injection of stem cells, 1000 U/kg EPO was injected. Before and after injury, trauma coordination performance was measured by the rotarod and inclined plane tests. Results Seven weeks after trauma, rat brains were examined by radiology and histology. Rotarod performance test did not change remarkably, even after the injury. Compared with group C, the SC+EPO group was found to have significant differences in the inclined plane test results. Conclusions Separately given, SCs and EPO have a positive effect on TBI, and our findings suggest that their coadministration is even more powerful. © 2016 Elsevier Inc. All rights reserved.
Description
ORCID
Keywords
Erythropoietin, Stem cell, Traumatic brain injury, CD34 antigen, erythropoietin, Ki 67 antigen, neuroprotective agent, animal experiment, animal tissue, Article, comparative study, controlled study, drug effect, experimental locomotor activity test, glia cell, healing, human, human cell, inclined plane test, locomotion, male, neuroimaging, neuropathology, nonhuman, nuclear magnetic resonance imaging, nuclear magnetic resonance scanner, phase 2 clinical trial (topic), rat, rotarod test, stem cell transplantation, therapy effect, traumatic brain injury, animal, brain, Brain Injuries, Traumatic, cord blood stem cell transplantation, diagnostic imaging, disease model, female, intraperitoneal drug administration, metabolism, multimodality cancer therapy, pathology, pathophysiology, treatment outcome, Wistar rat, Animals, Antigens, CD34, Brain, Combined Modality Therapy, Cord Blood Stem Cell Transplantation, Disease Models, Animal, Female, Humans, Injections, Intraperitoneal, Magnetic Resonance Imaging, Male, Neuroprotective Agents, Rats, Wistar, Rotarod Performance Test, Treatment Outcome, Male, cord blood stem cell transplantation, Wistar, Antigens, CD34, Wistar rat, Erythropoietin; Stem cell; Traumatic brain injury, inclined plane test, Traumatic brain injury, Brain Injuries, Traumatic, rat, animal, CD34 antigen, nuclear magnetic resonance imaging, Animals; Antigens, CD34/metabolism; Brain/diagnostic imaging/pathology/physiopathology; Brain Injuries, Traumatic/diagnostic imaging/pathology/physiopathology/*therapy; Combined Modality Therapy; *Cord Blood Stem Cell Transplantation; Disease Models, Animal; Erythropoietin/*administration & dosage; Female; Humans; Injections, Intraperitoneal; Magnetic Resonance Imaging; Male; Neuroprotective Agents/*administration & dosage; Rats, Wistar; Rotarod Performance Test; Treatment Outcome, multimodality cancer therapy, comparative study, experimental locomotor activity test, pathophysiology, Stem cell, neuroimaging, traumatic brain injury, drug effect, neuroprotective agent, Brain, healing, Combined Modality Therapy, Magnetic Resonance Imaging, locomotion, female, Neuroprotective Agents, Treatment Outcome, nuclear magnetic resonance scanner, Female, erythropoietin, rotarod test, Cord Blood Stem Cell Transplantation, Injections, Intraperitoneal, diagnostic imaging, brain, animal experiment, 610, stem cell transplantation, Article, Injections, animal tissue, male, Animals, Humans, Intraperitoneal, controlled study, human, Antigens, Rats, Wistar, glia cell, Erythropoietin, neuropathology, nonhuman, Animal, human cell, disease model, therapy effect, Rats, Disease Models, Animal, intraperitoneal drug administration, Rotarod Performance Test, Disease Models, phase 2 clinical trial (topic), treatment outcome, Ki 67 antigen, pathology, CD34, metabolism
Fields of Science
0302 clinical medicine, 03 medical and health sciences
Citation
WoS Q
Scopus Q

OpenCitations Citation Count
10
Source
Volume
89
Issue
Start Page
355
End Page
361
Collections
Yükleniyor...
